Abstract
The findings from the RASER study, reported by Edward Kim and colleagues,1 highlight the versatility of radioembolisation, which has evolved from a historically palliative lobar cancer treatment into a segmental, ablative, therapy with curative intent. This paradigm shift began in 2016, with the PREMIERE trial,2 a single-centre, randomised trial for unresectable hepatocellular carcinoma not amendable to thermal ablation. PREMIERE showed a significant time-to-progression (TTP) advantage of segmental radioembolisation versus conventional chemoembolisation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
